Drug pricing is one area where there may be potential future policy changes that impact community oncologists, said Dan Todd, JD, principal at Todd Strategy.
Drug pricing is one area where there may be potential future policy changes that impact community oncologists, said Dan Todd, JD, principal at Todd Strategy.
Transcript (slightly modified)
What big policy issues and changes, other than the Affordable Care Act, should community oncologists keep an eye on?
I think drug pricing is still a really big issue, I don’t think it is necessarily going to go away, and I think that it’ll likely be impacted in several different avenues. One is with faster approvals at the FDA, which will certain impact practices. I think the focus on cost and some of those drivers, so things like the 340B program, that the administration has turned its attention to. So, to me the impact of drug pricing and its bleed effect on market consolidation will continue to be a big issue.
With so much bipartisan interest in drug pricing, do you expect to see any legislation in this area, and what might it look like?
I think that there will always be a focus on cost pressures. I think it’s a really complicated issue, particularly for Congress. There’s obviously a lot of politics around it and there’s a lot of support for innovation, generally, and reimbursement rates impact where investments are made and I think they’re aware of that.
I do think that particularly with some of the more novel drug launches, that are going to be happening, with some fairly high prices, the dialogue will continue. I don’t see necessarily an opportunity for broad fundamental changes. I think that healthcare has been a difficult issue for the Republicans in Congress and we’re very quickly running out of a legislating window so I think a lot is going to happen at the administration level.
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More